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Anti-arrhythmic drug therapy carries an understood risk for
toxic side effects, even at therapeutic doses. In cases of high
dose ingestion these toxic effects can present rapidly with
extra-cardiac symptoms, malignant arrhythmias and life-
threatening hemodynamic deterioration. Prescribing clini-
cians should maintain familiarity with the mechanisms and
kinetics of the anti-arrhythmic drugs they prescribe, as well
as the clinical manifestations of anti-arrhythmic drug tox-
icity. Here we present a case of intentional ﬂecainide
overdose complicated by amphetamine co-ingestion. We
hope this case illustrates the importance of prompt symptom
recognition, mechanism-directed medical management and
the utility of short term mechanical hemodynamic support in
the management of anti-arrhythmic drug toxicity.
Case Presentation
A 23-year-old man with a medical history of symptomatic
premature atrial complexes and paroxysmal atrial tachy-
cardia, bicuspid aortic valve without signiﬁcant stenosis or
regurgitation, and severe depression with several prior
suicide attempts presented to an outside hospital emer-
gency department after ingesting a large but unknown
quantity of dextroamphetamine-amphetamine and ﬂecai-
nide pills. An electrocardiogram (ECG) obtained 1 month
prior to presentation was normal. An echocardiogram
performed at that time revealed normal biventricular
systolic function.
He was initially conscious but later became unresponsive.
He was noted to be in a persistent wide complex rhythm
(Figure 1) that quickly degenerated to pulseless ventricular
tachycardia and ventricular ﬁbrillation requiring resuscita-
tion and multiple deﬁbrillations. After return of spontaneous
circulation, he was intubated, started on a sodium bicarbon-
ate infusion, and transferred to our coronary intensive care
unit. Urine toxicology results were positive for cannabinoids,KEYWORDS Flecainide; Overdose (Heart Rhythm Case Reports 2016;2:228–231)
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examination were signiﬁcant for an elevated lactate concen-
tration at 4.6 mmol/L, preserved renal function, and mildly
elevated hepatic transaminases. His condition was initially
managed with oral gastric-tube suctioning, high-dose hyper-
tonic sodium bicarbonate, aggressive potassium and magne-
sium supplementation, hyperventilation to maintain a
relative alkalotic state, and intravenous lipid emulsion.
Although his QRS transiently narrowed with this manage-
ment, he later developed progressive QRS widening
(Figure 2) and recurrent hemodynamically unstable episodes
of ventricular tachycardia that were refractory to intravenous
amiodarone and lidocaine infusions and required progressive
vasopressor support. Transvenous pacing at rates above his
slow ventricular tachycardia was attempted, but his hemo-
dynamics worsened. Given his continued clinical deterio-
ration despite multiple and varied attempts to medically
manage his overdose, we opted to pursue mechanical
circulatory support with percutaneous venoarterial extrac-
orporeal membrane oxygenation (ECMO), which was
initiated approximately 8 hours after initial presentation.
Access for ECMO was obtained via the femoral artery
and vein. Femoral arteriography prior to ECMO placement
revealed small-caliber arteries, likely secondary to profound
vasoconstriction, which restricted cannula size and subse-
quent ﬂow rates. Cannulation and ECMO initiation were
otherwise uncomplicated. His echocardiogram following
ECMO initiation demonstrated severely reduced biventricular
function and profound ventricular dyssynchrony (Video 1).
He endured several hemodynamically signiﬁcant wide com-
plex rhythms necessitating repeat cardioversion though
systemic perfusion was maintained via ECMO. By hospital
day 3, he maintained normal sinus rhythm with narrowing of
his QRS despite a persistently elevated ﬂecainide level at
2.00 mg/mL (therapeutic range 0.20–1.00 mg/mL). His renal
function remained unaffected throughout his admission and
his transaminase levels improved. He tolerated an ECMO
turndown and was decannulated on hospital day 5. Shortly
afterward, he was extubated and transferred to the regular
nursing ﬂoor. His remaining hospital course was compli-
cated by health care–associated pneumonia, and he was
discharged home on hospital day 12. Flecainide was notpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.12.013
KEY TEACHING POINTS
 Lethal consequences of ﬂecainide overdose may be
more likely with coingestion of amphetamines
secondary to pharmacodynamics and
pharmacokinetic interactions.
 High-dose hypertonic sodium bicarbonate is the
mainstay of medical therapy of ﬂecainide overdose
and should be dosed aggressively (initial 50–100
mEq bolus with subsequent therapy to get pH4
7.5 and sodium concentration 4 150 mEq/L).
 Mechanical circulatory support should be given
early consideration in cases of coingestion of
medications that may potentiate the cardiotoxic
effects of ﬂecainide, such as amphetamines.
229Vu et al Flecainide Overdoserestarted on discharge, and he subsequently underwent a
successful atrial tachycardia ablation. His echocardiogram
prior to discharge showed a return to normal biventricular
function, and his ECG also normalized (Figure 3).Discussion
Flecainide is a Vaughan Williams class IC lipophilic antiar-
rhythmic agent indicated for patients with supraventricular
arrhythmias without evidence of ischemic or structural heart
disease. Flecainide exerts its action by delaying phase 0
depolarization through its high-afﬁnity binding for open-
state sodium channels. Physiologically, this results in a
slowing of conduction in the atria, ventricles, and His-Figure 1. Electrocardiogram obtained upon arrivalPurkinje system along with an increased refractory period
in ventricular tissue.1 The sodium channel–blocking proper-
ties of ﬂecainide are use-dependent in that the effects are
potentiated by increasing heart rate.
Flecainide is known to have proarrhythmic potential even
at usual doses, particularly in patients with underlying
coronary artery disease or structural heart disease.2 Bradyar-
rhythmias and QRS widening result from slowing of con-
duction in the atrial and ventricular myocytes as well as the
His-Purkinje ﬁbers in a dose-dependent fashion. Addition-
ally, tachyarrhythmias, particularly ventricular tachycardia,
frequently complicate ﬂecainide overdose, and an increased
propensity toward ventricular tachycardia may even be seen
at normal doses. There are limited experimental data
regarding the mechanism, but it has been proposed that the
cause is nonuniform conduction slowing and prolonging of
the ventricular myocyte refractory period, leading to the
development of reentrant circuits.3,4
Flecainide toxicity is rare but potentially fatal, with a
mortality rate upward of 10%.5 Symptoms of toxicity include
noncardiac manifestations, such as nausea, vomiting, and
seizures, as well as cardiac manifestations, including brady-
cardia, widening of the QRS complex, and ventricular
tachyarrhythmia.5 The management strategy for ﬂecainide
toxicity has been studied only through case reports, and
successful management can be extremely challenging given
its high oral bioavailability (approximately 90%) and slow
rate of elimination. Flecainide is not effectively dialyzed,
likely because of its large volume of distribution. The
mainstay of medical therapy has been the use of high-dose
sodium bicarbonate to offset the cardiotoxic effects of the
drug by inducing a high-dose sodium load along with serumto the outside hospital emergency department.
Figure 2. Electrocardiogram obtained after attempted medical management and prior to the initiation of venoarterial extracorporeal membrane oxygenation
(ECMO).
Heart Rhythm Case Reports, Vol 2, No 3, May 2016230alkalinization. This therapy alone has been shown to rescue
patients from even life-threatening overdose.6
Though the molecular mechanism underlying drug pH
and drug-sodium concentration is not completely under-
stood, increases in both sodium ion concentration and pHFigure 3. Electrocardiogram obtaihave been shown to reverse the ﬂecainide effect in canine
Purkinje ﬁbers. This phenomenon is thought to be mediated
by competitive inhibition and electrostatic repulsion prevent-
ing ﬂecainide binding. Alkalinization also facilitates ﬂecai-
nide dissociation from the sodium channel–binding site.7,8ned prior to hospital discharge.
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ﬂecainide overdose has included antiarrhythmics, intrave-
nous fat emulsion, and transvenous or transcutaneous pacing
to treat cardiac arrhythmias.9–12 Amiodarone and lidocaine
have been reported as effective, though the mechanism is not
entirely clear.10,11 Overdrive pacing has not been effective in
suppressing tachyarrhythmias, likely because of the use-
dependent properties of the drug, though pacing is effective
in treating signiﬁcant bradyarrhythmia.9,13 Success has been
reported with intravenous fat emulsion, which is thought to
sequester the lipophilic drug and decrease the amount of drug
available to the sodium channel receptors.12
Mechanical circulatory support with ECMO has been
previously reported in cases of life-threatening ﬂecainide
toxicity after the failure of medical therapy.9,14 ECMO is
the preferred method of mechanical support in this type
of toxicity as its function is not dependent on a perfusing
cardiac rhythm and it provides biventricular support. The
maintenance of hepatic and renal perfusion (and there-
fore function) also helps to hasten elimination of the
drug.
Notably, our patient’s case was complicated by coinges-
tion of dextroamphetamine-amphetamine, which may have
contributed to the severity of his presentation. Amphetamine
toxicity is known to cause β-adrenergic receptor stimulation
and can cause cardiac tachyarrhythmia. Polypharmacy
ingestion is commonly encountered in suicide attempts,
especially in young U.S. adults, for whom poisoning is
among the most common modes of suicide attempt.15
Therapy frequently must address multiple toxicities in these
cases. Given the presentation of our patient with a wide
complex rhythm in the absence of the typical neurologic
signs of amphetamine toxicity, we concluded that ﬂecainide
was the primary driver for his clinical instability, and the
patient was treated accordingly.
Conclusion
Flecainide overdose may cause potentially fatal arrhythmia,
myocardial depression, and ventricular dyssynchrony.
Hypertonic sodium bicarbonate is the mainstay of medical
therapy, though there may be a role for other antiarrhythmics
and intravenous fat emulsion. In the failure of initial medicaltherapy, consideration should be given to the early use of
venoarterial ECMO, which can provide life-saving hemody-
namic support and promote natural drug clearance.Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrcr.2015.
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